AI주식인사이트AI Stock Insight
C

프레스티지바이오파마

950210KOSPI

46.0 / 100

Reference Date: 2026-10-23

Financial Score16.5 / 40
News Sentiment12.5 / 25
Momentum7.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 11.6% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Prestige BioPharma is a biopharmaceutical company specializing in biosimilars and monoclonal antibody drug development. Its Herceptin biosimilar HD201 received a positive opinion from the European Medicines Agency (EMA) in 2024, while Avastin biosimilar HD204 and Humira biosimilar PBP1502 are in development. The company's pancreatic cancer treatment antibody drug PBP1510 holds patents in 13 countries, and its CTHRC1-targeting antibody drug PBP1710 is also in development.

Number of Employees

67people

Average Salary

53.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
105874.98Industry Average 15.000.0Point

7058.3x industry avg (risky)

PBR
—Industry Average 1.203.5Point
ROE
0.80Industry Average 8.001.0Point

Well below industry avg

Debt Ratio
14.17Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲1098.9% (2-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲4.3% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -4.9% (improving, 2yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (2%, downtrend)

Current 5,240Won52-week high 13,75052-week low 5,030
1-month return1.0Point

1m -11.64% (falling)

Volume trend5.0Point

Volume flat

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0
  • Neutral정기주주총회결과2026-09-29
  • Neutral독립이사의선임ㆍ해임또는중도퇴임에관한신고2026-09-29
  • Neutral유가증권시장상장외국법인외부감사인선임ㆍ해임ㆍ변경신고서2026-09-29